Prism author Stefan Stern from the London-based Financial Times recently had a chance to catch up with Arthur D. Little's new global CEO, Michael Träm, who has just finished his first 200 days at the firm. In a long conversation Träm discussed the strengths of Arthur D.
The pharmaceutical industry is in crisis. Big, profitable products are losing their patent protection and generic producers are jumping in to take a growing share of the market. We look at how the big pharmas, and the smaller ones, can find a way through these troubled times.
The Nineties saw a whole wave of market liberalisations. Arthur D. Little has helped former monopolies and market entrants alike in designing strategies for liberalised markets. Read about the views and conclusions from a new entrant's perspective.
When the reengineering wave of the 1990s hit R&D operations, Chief Technology Officers (CTOs) jumped to justify their companies' R&D spending levels, striving for functional efficiency, process effectiveness, and value for money invested.